HUTCHMED (China) Limited is a global biopharmaceutical company committed to the discovery, development, and commercialisation of targeted therapeutics and immunotherapies. With operations primarily in China, it offers solutions for the treatment of cancer and immunological diseases.
HUTCHMED and its subsidiaries operate within the biotechnology and pharmaceutical sector, focused on oncology and immunology. HUTCHMED provides new treatment options and has strategic collaborations with other global pharmaceutical companies. Its pipeline includes various small molecule, antibody-based, and cell-therapy programs.
Monitor the HCM share price by adding it to your eToro watchlist.